SCHEMBL196509

SCHEMBL196509

Brc1cccc2cccnc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.64
KDM4E B2RXH2 5/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
MMP2 P08253 2/20 0.64
TSHR P16473 2/20 0.64
CYP3A4 P08684 2/20 0.64
MAPT P10636 2/20 0.64
TP53 P04637 2/20 0.64
HSP90AA1 P07900 2/20 0.64
HTT P42858 2/20 0.64
TDP1 Q9NUW8 2/20 0.64
GMNN O75496 1/20 0.64
CYP2D6 P10635 1/20 0.64
MMP9 P14780 1/20 0.64
ALOX15 P16050 1/20 0.64
NFKB1 P19838 1/20 0.64
MMP8 P22894 1/20 0.64
CCR1 P32246 1/20 0.64
THPO P40225 1/20 0.64
MTOR P42345 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL28285432 0.98 LMNA (0.61) LMNAKDM4ESMN1; SMN2MMP2TSHR
SCHEMBL31170763 0.85 LMNA (0.58) LMNAKDM4ESMN1; SMN2MMP2TSHR
SCHEMBL2336321 0.85 LMNA (0.58) LMNAKDM4ESMN1; SMN2MMP2TSHR
SCHEMBL751713 0.82 LMNA (0.56) LMNAKDM4ESMN1; SMN2MMP2TSHR
Phenanthroline SCHEMBL29354015 0.78 CCR1 (1.00) LMNAKDM4ESMN1; SMN2MMP2TSHR
Phenanthroline SCHEMBL8312 0.78 CCR1 (1.00) LMNAKDM4ESMN1; SMN2MMP2TSHR
Phenanthroline SCHEMBL8845760 0.78 CCR1 (1.00) LMNAKDM4ESMN1; SMN2MMP2TSHR
Phenanthroline SCHEMBL29367277 0.78 CCR1 (1.00) LMNAKDM4ESMN1; SMN2MMP2TSHR
Phenanthroline SCHEMBL18113452 0.77 CCR1 (0.84) LMNAKDM4ESMN1; SMN2MMP2TSHR
SCHEMBL1282008 0.77 CCR1 (0.75) LMNAKDM4ESMN1; SMN2MMP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119702019-A Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof 湘潭大学 2025-03-28 CN claimed
CN-110270295-B Preparation method of amino-substituted benzopyridine nitrogen-containing heterocycle 北京六合宁远科技有限公司 2021-08-24 CN claimed
CN-110270295-A Preparation method of amino-substituted phenylpropylpyridine nitrogen-containing heterocycle 北京六合宁远科技有限公司 2019-09-24 CN claimed
CN-110041905-A Fluorescence and the dual luminescent material of phosphorescence with switching effect and preparation method thereof 华中科技大学 2019-07-23 CN claimed
CN-104876863-B Fluorescent probe compound and preparation method and application thereof 北京农学院 2017-02-22 CN claimed
CN-105753838-A Novel high-regioselectivity amination method of quinoline derivatives 安阳师范学院 2016-07-13 CN claimed
CN-104876863-A Fluorescent probe compound and preparation method and application thereof UNIV BEIJING AGRICULT 2015-09-02 CN claimed
CN-104592109-A Method for preparing 8-bromoquinoline derivative Hunan huateng pharmaceutical co ltd 2015-05-06 CN claimed
CN-103467374-A Synthesis method of 8-bromine-4-carboxyl quinoline CHEMFUTURE PHARMATECH JIANGSU CO LTD 2013-12-25 CN claimed
CN-101602723-A The preparation method of 2-methyl-8-quinolylamine UNIV HUNAN (CN) 2009-12-16 CN claimed
CN-100422201-C Arylation method for the functionalization of O-allyl erythromycin derivatives ABBOTT LAB (US) 2008-10-01 CN claimed
EP-1399458-B1 AN ARYLATION METHOD FOR THE FUNCTIONALIZATION OF O-ALLYL ERYTHROMYCIN DERIVATIVES ABBOTT LAB (US) 2005-08-03 EP claimed
CN-1633443-A Arylation method for the functionalization of O-allyl erythromycin derivatives ABBOTT LAB (US) 2005-06-29 CN claimed
EP-1399458-A1 AN ARYLATION METHOD FOR THE FUNCTIONALIZATION OF O-ALLYL ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 2004-03-24 EP claimed
US-20030125531-A1 Arylation method for the functionalization of O-allyl erythromycin derivatives ABBVIE INC. 2003-07-03 US claimed
WO-2002096922-A1 AN ARYLATION METHOD FOR THE FUNCTIONALIZATION OF O-ALLYL ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 2002-12-05 WO claimed
EP-0365863-B1 Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMA (US) 1994-08-17 EP claimed
US-4999431-A Reacting A Bromoquinoline Compound With Butyllithium And An N-Methyl-N-Methoxyalkanamide; Intermediates for Quinolyloxazole-2-ones MERRELL DOW PHARMACEUTICALS (US) 1991-03-12 US claimed
CN-1042145-A New quinolyl  azoles-2-ketone compounds as inhibitors of protein kinase C MERRELL DOW PHARMA (US) 1990-05-16 CN claimed
EP-0365863-A2 Novel quinolyloxazole-2-ones useful as proteinkinase C inhibitors MERRELL DOW PHARMACEUTICALS INC. (US) 1990-05-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125531-A1 Arylation method for the functionalization of O-allyl erythromycin derivatives EEF2K, DEK, FRK LMNA 4574/4885KDM4E 735/4885SMN1; SMN2 2984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.